CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Dechra Pharmaceuticals PLC - DPH CFD

38.18
0.05%
Market Trading Hours* (UTC) Opens on Monday at 08:00

Mon - Fri: 08:00 - 16:30

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.20
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.025262 %
Charges from full value of position ($-1.01)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.025262%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003344 %
Charges from full value of position ($0.13)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
0.003344%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency GBP
Margin 20%
Stock exchange United Kingdom of Great Britain and Northern Ireland
Commission on trade 0%

*Information provided by Capital.com

Dechra Pharmaceuticals PLC ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 38.16
Open* 38.16
1-Year Change* 41.12%
Day's Range* 38.16 - 38.2
52 wk Range 24.73-40.00
Average Volume (10 days) 892.50K
Average Volume (3 months) 17.33M
Market Cap 4.35B
P/E Ratio -100.00K
Shares Outstanding 113.89M
Revenue 761.50M
EPS -0.24
Dividend (Yield %) 1.1876
Beta 0.95
Next Earnings Date Feb 27, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Nov 30, 2023 38.16 0.02 0.05% 38.14 38.18 37.92
Nov 29, 2023 38.16 0.04 0.10% 38.12 38.20 38.12
Nov 28, 2023 38.16 0.08 0.21% 38.08 38.16 38.08
Nov 27, 2023 38.16 0.26 0.69% 37.90 38.16 37.90
Nov 24, 2023 38.14 0.04 0.10% 38.10 38.14 38.10
Nov 23, 2023 38.12 0.02 0.05% 38.10 38.14 38.10
Nov 22, 2023 38.12 0.34 0.90% 37.78 38.12 37.78
Nov 21, 2023 38.10 0.02 0.05% 38.08 38.10 38.04
Nov 20, 2023 38.10 0.00 0.00% 38.10 38.16 38.06
Nov 17, 2023 38.14 0.44 1.17% 37.70 38.24 37.50
Nov 16, 2023 37.70 -0.02 -0.05% 37.72 37.80 37.66
Nov 15, 2023 37.54 -0.20 -0.53% 37.74 37.80 37.52
Nov 14, 2023 37.76 0.06 0.16% 37.70 37.82 37.56
Nov 13, 2023 37.76 0.42 1.12% 37.34 37.78 37.34
Nov 10, 2023 37.70 -0.04 -0.11% 37.74 37.78 37.64
Nov 9, 2023 37.76 0.02 0.05% 37.74 37.88 37.64
Nov 8, 2023 37.68 0.14 0.37% 37.54 37.78 37.54
Nov 7, 2023 37.72 0.00 0.00% 37.72 37.82 37.72
Nov 6, 2023 37.82 0.06 0.16% 37.76 37.86 37.72
Nov 3, 2023 37.72 -0.04 -0.11% 37.76 37.82 37.58

Dechra Pharmaceuticals PLC Events

Time (UTC) Country Event
Wednesday, December 13, 2023

Time (UTC)

10:59

Country

GB

Event

Dechra Pharmaceuticals PLC Annual Shareholders Meeting
Dechra Pharmaceuticals PLC Annual Shareholders Meeting

Forecast

-

Previous

-
Tuesday, February 27, 2024

Time (UTC)

10:59

Country

GB

Event

Half Year 2024 Dechra Pharmaceuticals PLC Earnings Release
Half Year 2024 Dechra Pharmaceuticals PLC Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2023 2022 2021 2020 2019
Total revenue 761.5 681.8 608 515.1 481.8
Revenue 761.5 681.8 608 515.1 481.8
Cost of Revenue, Total 331.9 296.5 262.1 223.5 203.6
Gross Profit 429.6 385.3 345.9 291.6 278.2
Total Operating Expense 776.6 599.8 521.2 465.4 443.8
Selling/General/Admin. Expenses, Total 207 178.6 151.3 134.9 125.7
Research & Development 57.5 32.4 32.4 28.4 25.1
Depreciation / Amortization 140.2 72.8 75.2 69.6 76.8
Unusual Expense (Income) 40 19.5 0.2 9 12.6
Operating Income -15.1 82 86.8 49.7 38
Interest Income (Expense), Net Non-Operating -21 -4.4 -12.8 -8.8 -10.2
Other, Net 0
Net Income Before Taxes -36.1 77.6 74 40.9 27.8
Net Income After Taxes -27.9 58.2 55.5 33.9 20.9
Minority Interest 0
Net Income Before Extra. Items -27.9 58.2 55.5 33.9 20.9
Net Income -27.9 58.2 55.5 33.9 30.9
Income Available to Common Excl. Extra. Items -27.9 58.2 55.5 33.9 20.9
Income Available to Common Incl. Extra. Items -27.9 58.2 55.5 33.9 30.9
Dilution Adjustment 0
Diluted Net Income -27.9 58.2 55.5 33.9 30.9
Diluted Weighted Average Shares 113.477 108.987 108.751 103.482 102.762
Diluted EPS Excluding Extraordinary Items -0.24587 0.53401 0.51034 0.32759 0.20338
Dividends per Share - Common Stock Primary Issue 0.4489 0.405 0.3429 0.316
Diluted Normalized EPS 0.57545 0.95974 0.72643 0.58561 0.59847
Total Extraordinary Items 10
Jun 2023 Dec 2022 Jun 2022 Dec 2021 Jun 2021
Total revenue 384.1 377.4 349.4 332.4 308.2
Revenue 384.1 377.4 349.4 332.4 308.2
Cost of Revenue, Total 174 158.1 153.3 143.2 133
Gross Profit 210.1 219.3 196.1 189.2 175.2
Total Operating Expense 436.8 339.8 324.2 275.6 262.9
Selling/General/Admin. Expenses, Total 104.5 102.5 96.8 81.8 76.5
Research & Development 31 26.5 18.9 13.5 17.3
Depreciation / Amortization 32.5 38.6 37.4 35.4 36.9
Unusual Expense (Income) 94.8 14.1 17.8 1.7 -0.8
Operating Income -52.7 37.6 25.2 56.8 45.3
Interest Income (Expense), Net Non-Operating -13.1 -7.9 -1 -3.4 -6.7
Other, Net
Net Income Before Taxes -65.8 29.7 24.2 53.4 38.6
Net Income After Taxes -50.5 22.6 17.5 40.7 32.2
Net Income Before Extra. Items -50.5 22.6 17.5 40.7 32.2
Net Income -50.5 22.6 17.5 40.7 32.2
Income Available to Common Excl. Extra. Items -50.5 22.6 17.5 40.7 32.2
Income Available to Common Incl. Extra. Items -50.5 22.6 17.5 40.7 32.2
Dilution Adjustment 0
Diluted Net Income -50.5 22.6 17.5 40.7 32.2
Diluted Weighted Average Shares 113.858 113.824 109.083 108.892 108.803
Diluted EPS Excluding Extraordinary Items -0.44353 0.19855 0.16043 0.37376 0.29595
Dividends per Share - Common Stock Primary Issue 0.125 0.3289 0.12 0.2939
Diluted Normalized EPS 0.75006 0.42873 0.49595 0.46376 0.46598
  • Annual
  • Quarterly
2023 2022 2021 2020 2019
Total Current Assets 467.9 444.4 392.2 448.9 291.5
Cash and Short Term Investments 74.4 120.9 118.4 227.4 80.3
Cash 74.4 120.9 118.4 227.4 80.3
Short Term Investments
Total Receivables, Net 169.6 142.1 119.2 97.3 103.8
Accounts Receivable - Trade, Net 144.2 122.1 88.2 79.4 91.1
Total Inventory 217.3 175.7 149.5 120.8 103.5
Prepaid Expenses 6.6 5.7 5.1 3.4 3.9
Total Assets 1569.4 1293.3 1214.1 1237.6 1041.5
Property/Plant/Equipment, Total - Net 159.3 100.3 87 76.4 58.4
Property/Plant/Equipment, Total - Gross 224.7 161.9 140 127.8 100.8
Accumulated Depreciation, Total -65.4 -61.6 -53 -51.4 -42.4
Goodwill, Net 334.5 245.4 236.1 253.8 245.7
Intangibles, Net 587.9 485.1 479.7 438.4 434.9
Long Term Investments 14.9 15.8 17.1 17.4 10.1
Other Long Term Assets, Total 4.9 2.3 2 2.7 0.9
Total Current Liabilities 164 158.7 155.8 137.3 118.1
Accounts Payable 43.4 46 35.2 34.6 31.9
Accrued Expenses 98.8 87.7 74.4 60.5 61.7
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 3.9 3.3 3.1 4.6 1.2
Other Current Liabilities, Total 17.9 21.7 43.1 37.6 23.3
Total Liabilities 814.2 626.5 581.2 600.1 532.4
Total Long Term Debt 500.6 325.8 317.6 353.1 309.6
Long Term Debt 487.6 313.7 304.8 341.3 309.6
Capital Lease Obligations 13 12.1 12.8 11.8 0
Deferred Income Tax 76.3 35.8 48.8 62.6 74.5
Minority Interest
Other Liabilities, Total 73.3 106.2 59 47.1 30.2
Total Equity 755.2 666.8 632.9 637.5 509.1
Common Stock 1.1 1.1 1.1 1.1 1
Additional Paid-In Capital 596 413.9 411.6 409.3 277.9
Retained Earnings (Accumulated Deficit) 171 248.4 232.1 210.8 208.6
Treasury Stock - Common -0.2
Other Equity, Total -12.7 3.4 -11.9 16.3 21.6
Total Liabilities & Shareholders’ Equity 1569.4 1293.3 1214.1 1237.6 1041.5
Total Common Shares Outstanding 113.888 108.393 108.215 108.011 102.652
Jun 2023 Dec 2022 Jun 2022 Dec 2021 Jun 2021
Total Current Assets 467.9 459.3 444.4 376 392.2
Cash and Short Term Investments 74.4 87.9 120.9 123.7 118.4
Cash & Equivalents
Total Receivables, Net 176.2 147.6 147.8 99.9 124.3
Accounts Receivable - Trade, Net 161.9 125.9 136.8 85.6 106.7
Total Inventory 217.3 223.8 175.7 149.4 149.5
Total Assets 1569.4 1744.3 1293.3 1177.7 1214.1
Property/Plant/Equipment, Total - Net 159.3 155.3 100.3 92.3 87
Intangibles, Net 922.4 1111.2 730.5 689.4 715.8
Long Term Investments 14.9 15.4 15.8 17.7 17.1
Other Long Term Assets, Total 4.9 3.1 2.3 2.3 2
Total Current Liabilities 164 168.4 158.7 129.2 155.8
Payable/Accrued 144.5 139.3 136.8 99.9 113.5
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 3.9 3.2 3.3 3.1 3.1
Other Current Liabilities, Total 15.6 25.9 18.6 26.2 39.2
Total Liabilities 814.2 902.6 626.5 538.6 581.2
Total Long Term Debt 500.6 508 325.8 313.7 315.5
Long Term Debt 500.6 508 325.8 313.7 315.5
Deferred Income Tax 76.3 124.8 35.8 43.4 48.8
Other Liabilities, Total 73.3 101.4 106.2 52.3 61.1
Total Equity 755.2 841.7 666.8 639.1 632.9
Common Stock 1.1 1.1 1.1 1.1 1.1
Additional Paid-In Capital 596 594.7 413.9 413.3 411.6
Retained Earnings (Accumulated Deficit) 171 235.4 248.4 242.3 232.1
Treasury Stock - Common -0.2
Other Equity, Total -12.7 10.5 3.4 -17.6 -11.9
Total Liabilities & Shareholders’ Equity 1569.4 1744.3 1293.3 1177.7 1214.1
Total Common Shares Outstanding 113.888 113.837 108.393 108.365 108.215
Cash 74.4 87.9 120.9 123.7 118.4
Other Current Assets, Total 0 3
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 95.5 84 52.2 39 34.1
Cash From Operating Activities 122.9 89.1 106.4 81.8 64
Cash From Operating Activities 11.1 11 9.9 5.7 4.8
Amortization 78 4.5 4.3 4.1 2.6
Non-Cash Items 6.5 77.7 69.8 79 63.1
Cash Taxes Paid 32.9 43.9 12.9 17.3 11.5
Cash Interest Paid 7.5 8.2 8.2 9.2 5.7
Changes in Working Capital -68.2 -88.1 -29.8 -46 -40.6
Cash From Investing Activities -78.3 -136.1 -81.5 -61.9 -241.7
Capital Expenditures -77.6 -134.8 -49.2 -22.5 -12.6
Other Investing Cash Flow Items, Total -0.7 -1.3 -32.3 -39.4 -229.1
Cash From Financing Activities -46.1 -55.1 118.9 -20.1 193.8
Financing Cash Flow Items 0 -1.7 -0.2 -3.9
Total Cash Dividends Paid -44.8 -37.9 -33.3 -28.4 -21.8
Issuance (Retirement) of Stock, Net 2.3 2.3 131.5 1.2 103.3
Issuance (Retirement) of Debt, Net -3.6 -19.5 22.4 7.3 116.2
Foreign Exchange Effects 4 -6.9 3.3 0.8 2.4
Net Change in Cash 2.5 -109 147.1 0.6 18.5
Dec 2022 Jun 2022 Dec 2021 Jun 2021 Dec 2020
Net income/Starting Line 44.6 95.5 57.4 84 40.3
Cash From Operating Activities 51.5 122.9 88.1 89.1 58.1
Cash From Operating Activities 6.2 11.1 5.2 11 5.3
Amortization 39.3 78 37.6 4.5 2.1
Non-Cash Items 3.9 6.5 1.4 77.7 41.2
Cash Taxes Paid 10.4 32.9 11.6 43.9 22.8
Cash Interest Paid 3.3 7.5 3.6 8.2 4.2
Changes in Working Capital -42.5 -68.2 -13.5 -88.1 -30.8
Cash From Investing Activities -408.2 -78.3 -49.8 -136.1 -116.2
Capital Expenditures -13.6 -77.6 -49.5 -134.8 -116.1
Other Investing Cash Flow Items, Total -394.6 -0.7 -0.3 -1.3 -0.1
Cash From Financing Activities 321.4 -46.1 -32 -55.1 -27.1
Financing Cash Flow Items 0 0
Total Cash Dividends Paid -37.4 -44.8 -31.8 -37.9 -25.9
Issuance (Retirement) of Stock, Net 180.8 2.3 1.7 2.3 1.3
Issuance (Retirement) of Debt, Net 178 -3.6 -1.9 -19.5 -2.5
Foreign Exchange Effects 2.3 4 -1 -6.9 -3.2
Net Change in Cash -33 2.5 5.3 -109 -88.4
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
BNP Paribas Asset Management France SAS Investment Advisor/Hedge Fund 6.7582 7697132 116493 2023-10-26 LOW
Barclays Wealth Investment Advisor/Hedge Fund 6.5827 7497298 475778 2023-10-26 MED
BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund 5.7701 6571802 -303696 2023-10-27 LOW
Société Générale Securities Services S.A. Research Firm 4.9038 5585132 -429889 2023-10-27 LOW
Ostrum Asset Management Investment Advisor 4.8093 5477494 13148 2023-10-27 MED
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 4.4274 5042517 23611 2023-10-26 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 3.4318 3908560 -20999 2023-09-14 LOW
NBC Global Finance, Ltd. Corporation 3.0452 3468246 -1137336 2023-10-26 MED
Bank of Nova Scotia Bank and Trust 3.0262 3446604 1123723 2023-10-27 MED
Brown Capital Management, LLC Investment Advisor 2.8876 3288786 -196740 2023-10-20 LOW
UBS Limited Research Firm 2.4145 2750008 1619452 2023-10-26 HIGH
J.P. Morgan Securities plc Research Firm 2.3944 2727124 -1236978 2023-09-25 MED
BlackRock Institutional Trust Company, N.A. Investment Advisor 1.7406 1982380 1989 2023-10-01 LOW
Legal & General Investment Management Ltd. Investment Advisor/Hedge Fund 1.7196 1958552 -35687 2023-10-27 LOW
Jefferies GmbH Hedge Fund 1.4955 1703250 328929 2023-07-21 LOW
Rathbone Unit Trust Management Limited Investment Advisor/Hedge Fund 1.3067 1488270 -305406 2023-10-27 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 1.1204 1276082 -12 2023-10-26 LOW
Baron Capital Management, Inc. Investment Advisor/Hedge Fund 1.1172 1272410 -120000 2023-08-18 LOW
Nuveen LLC Pension Fund 1.0909 1242443 -83027 2023-08-17 LOW
Goldman Sachs International Research Firm 1.0499 1195823 1195823 2023-06-09 MED

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Dechra Pharmaceuticals Company profile

About Dechra Pharmaceuticals plc

Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development. The European Pharmaceuticals Segment includes Dechra Veterinary Products Europe, Dechra Veterinary Products International and Dechra Pharmaceuticals Manufacturing. It manufactures and markets companion animal, equine, food producing animal products and nutrition. The North American (NA) Pharmaceuticals segment consists of Dechra Veterinary Products US, Dechra Produtas Veterinarios (Mexico) and Dechra Veterinary Products Canada, which sells companion animal, equine and food producing animal products. The segment also includes its manufacturing units based in Melbourne, Florida and Fort Worth, Texas.

Financial summary

BRIEF: For the six months ended 31 December 2021, Dechra Pharmaceuticals plc revenues increased 11% to £332.4M. Net income increased 75% to £40.7M. Revenues reflect NA Pharmaceuticals segment increase of 21% to £126.3M, European Pharmaceuticals segment increase of 5% to £206.1M. Net income benefited from NA Pharmaceuticals segment income increase of 20% to £43.6M, European Pharmaceuticals segment income increase of 7% to £69.7M.

Equity composition

12/2007, Rights Issue, 11 new shares for every 50 shares held @ GBp 303 (Factor: 1.018155). 04/2012, Rights Issue, 3 new shares for every 10 shares held @ GBp 300 (Factor: 1.103196).

Industry: Veterinary Drugs

24 Cheshire Avenue
Cheshire Business Park
NORTHWICH
CHESHIRE CW9 7UA
GB

Income Statement

  • Annual
  • Quarterly

News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023
GBP

UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

10:48, 21 November 2023

People also watch

US100

16,001.20 Price
+0.470% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 7.0

Gold

2,072.25 Price
+1.760% 1D Chg, %
Long position overnight fee -0.0193%
Short position overnight fee 0.0111%
Overnight fee time 22:00 (UTC)
Spread 0.30

Oil - Crude

74.50 Price
-1.560% 1D Chg, %
Long position overnight fee -0.0136%
Short position overnight fee -0.0083%
Overnight fee time 22:00 (UTC)
Spread 0.040

XRP/USD

0.62 Price
+0.830% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading